Pharma Pulse: Walgreens’ New Hybrid Pharmacist Model, Pharmacies Expand Injectable Access, and More
Walgreens is launching a hybrid pharmacist model that blends in‑store duties with centralized, remote clinical work to ease staffing pressures and boost medication therapy management. A new study highlights community pharmacies’ expanding role as key sites for immunizations and injectable therapies, improving access in underserved areas. GoodRx and Eli Lilly are partnering to make the newly approved GLP‑1 drugs Foundayo and Zepbound more affordable through cash‑pay programs, extending direct‑to‑consumer options. Meanwhile, Regeneron‑Telix’s multibillion‑dollar radiopharma deal underscores rising investment in precision oncology, and AbbVie secured an exclusive licensing agreement with Haisco worth up to $745 million for assets outside Greater China.
LogiPharma Europe: Richard Harrop on Packaging Innovation
Richard Harrop, product director at Topa Thermal, outlined how cold‑chain packaging must juggle sustainability, performance, and real‑world resilience ahead of his LogiPharma Europe 2026 presentation. He warned that traditional materials such as EPS, polyurethane and vacuum insulation face growing regulatory...
LogiPharma 2026: Seamus Keane on Building Smarter Supply Networks
Seamus Keane, VP of Pharma and Healthcare for Europe at Kuehne+Nagel, will lead a LogiPharma Europe 2026 panel on building intelligent, resilient supply networks. He argues that resilience must be embedded in network architecture through data, scenario modeling, and end‑to‑end visibility rather...
LogiPharma 2026: How Automation Is Reshaping Pharma Supply Chains
At LogiPharma 2026, Cold Chain Technologies’ chief commercial officer Anthony “TJ” Rizzo emphasized that automation and real‑time monitoring are redefining pharmaceutical cold‑chain logistics. He explained that end‑to‑end visibility can shift companies from reactive, post‑delivery investigations to proactive risk mitigation. Regulators are...
How GLP-1s Are Shifting Pharma Commercialization Trends
The GLP‑1 class has evolved from a niche injectable therapy to a high‑volume market that now includes oral formulations, prompting pharma to pivot toward larger total addressable markets. Over the past decade the industry focused on ultra‑rare, high‑price drugs, but...
How to Optimize a Hub Model for Efficiency and Commercial Success
Traci Miller, senior director of Access and Patient Support at Sonexus (Cardinal Health), explains how hybrid hub services are shifting from basic benefit verification to strategic partners that manage specialty product onboarding, adherence, and data analytics. Digital intake and prior‑authorization...
Jessica Ledesma on Navigating the New Era of Hospital Cold Storage Resilience
The rapid growth of biosimilars and high‑value specialty drugs is straining hospital pharmacy cold‑storage capacity, according to Jessica Ledesma, product manager at Swisslog Healthcare. Aging refrigeration units now pose a heightened risk of costly inventory loss and treatment interruptions. Hospitals...
Why Streamlining Support Is Key to Long-Term Adherence
In a final interview with Pharmaceutical Commerce, ConnectiveRx chief commercial officer Laura Blair argues that simplifying patient‑support workflows is essential for sustaining long‑term adherence to specialty therapies. She calls for “cleaner” digital tools that embed enrollment and diagnostic assistance directly...
How to Master the Pharmacovigilance System Master File for Inspection Readiness
Mastering the Pharmacovigilance System Master File (PSMF) is essential for inspection readiness, as regulators use it to gauge a company’s PV compliance before any formal interview. In the EU and UK, the PSMF must be supplied within seven days of...
Laura Blair: Rethinking Hub Efficiency and the Role of AI in Patient Support
ConnectiveRx’s chief commercial officer Laura Blair says specialty‑pharma patient‑support hubs are under‑utilized, with only 10‑15% of eligible patients engaging. She attributes the gap to design and access flaws rather than technology, noting that cumbersome enrollment and regulatory hurdles deter usage....
Pharma Pulse: Tariffs, a Ceasefire, and Patient Access
The U.S. Commerce Department announced a 100% base tariff on imported active pharmaceutical ingredients and patented drugs, urging manufacturers to shift production domestically. Companies can avoid the full rate by securing a most‑favored‑nation pricing agreement or by filing an onshoring...
Laura Blair: Balancing Virtual Fulfillment and Traditional Pharmacy Distribution
ConnectiveRx chief commercial officer Laura Blair says direct‑to‑patient (DTP) models and virtual fulfillment are reshaping pharmaceutical distribution, a shift accelerated by the surge in GLP‑1 therapies. She stresses that true DTP value lies in integrated benefits verification that matches patients...
Copay Funds Are Being Misused at the Pharmacy. Now There’s a Way to Stop It in Real Time
Pharmaceutical manufacturers rely on copay assistance programs to boost patient access and drug utilization, but misuse at the pharmacy level is eroding billions in spend. ConnectiveRx’s ShieldRx platform intervenes at the moment a claim is submitted, using AI‑driven analytics to...
The Role of Class of Trade Research in Pharmaceutical Market Access
Manasi Salgaonkar highlights that class of trade (CoT) research is essential for precise pharmaceutical pricing, contract eligibility, and regulatory compliance. Accurate CoT classification links dispensing settings—retail, hospital, specialty, mail‑order, and IDNs—to specific pricing tiers and rebate agreements. Continuous updates are...
Op/Ed: Why Rare Disease Brands Are Losing Patients at Critical Moments
Anthony Bianciella argues rare‑disease brands lose patients because their HCP journey maps stop at prescribing intent, neglecting the complex post‑diagnosis steps such as referrals, prior authorizations and hub enrollment. He explains that specialists see these handoffs rarely, so the process...
